Novo Nordisk
NVO,
has entered into exclusive negotiations to acquire a controlling stake in French medical device maker Biocorp in a deal that values Biocorp at 154.4 million euros, or about $165 million, the companies said in a release. The companies have been collaborating since 2021 on an add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes and are looking to expand its use to other therapy areas, the companies said. Biocorp makes Mallya, a Bluetooth enabled smart add-on device for pen injectors. Novo Nordisk is “looking to increase agility to enable faster innovation and development of novel connected devices,” senior vice president Marianne Olholm said in a statement. Novo Nordisk shares were up 1.1% in premarket trading on Monday.
